The challenge with today’s ICMs isn’t what they’re missing. It’s what they have too much of: Excessive false positives and unnecessary appointments to adjust programming.

The LUX-Dx ICM System is designed to change all that with a dual-stage algorithm to help reject false positives, remote programming to put you in control and advanced technologies to streamline patient care. It’s more of what you want in an ICM—and less of what you don’t.

It's time for an ICM like no other.

__________________________________

An ICM That Checks its Work

The LUX-Dx ICM features a dual-stage algorithm that automatically detects and then verifies data before sending results, so it can reject false positives, provide actionable insights and get you to an accurate diagnosis faster. It’s time for data you can count on.

 

Advanced Control, on Your Terms
 

Combining remote programming and the new LATITUDE Clarity™ Data Management System, the LUX-Dx ICM System helps you accelerate critical decision making and increase efficiency—without having to make another patient appointment. It’s time to put the power in your hands.   

Reliable Data for You. Peace of Mind for Patients

The myLUX™ Patient App helps patients feel confident that their heart rhythms are being monitored, while helping improve compliance and educate patients. It’s time for more informed patients.

 
_________________________________

Boston Scientific has announced winning FDA clearance for its LUX-Dx Insertable Cardiac Monitor (ICM), an implant that can detect hard-to-spot cardiac arrhythmias, such as atrial fibrillation, and help diagnose their origin.

The device’s detection algorithm has two separate components, one of which detects a suspect arrhythmia and the other verifies the finding. Once an arrhythmia is confirmed, the wireless device sends a signal to the patient’s cardiologist via an app installed on the patient’s phone. Having a double-checking component within the implant’s brains helps to prevent false positive alarms.

To help cardiologists get the most out of the monitor, and as a side benefit during the ongoing COVID-19 pandemic, the LUX-Dx can be re-programmed by the physician remotely to adjust its arrhythmia detection settings. Other similar devices involve patients visiting their doctors for a change in programming to happen.

The device can spot atrial fibrillation (AFib), rhythm pause, atrial flutter, bradycardia, and tachycardia within certain parameters that are defined by the physician.

“For physicians, receiving accurate monitoring data and having remote access to programming provides the opportunity to operate with more efficiency and confidence,” said Kenneth Stein, M.D., senior vice president and chief medical officer, Rhythm Management and Global Health Policy, Boston Scientific, in a press release. “The LUX-Dx ICM System is designed to provide physicians the ability to accelerate critical clinical decisions and allow them to spend more time focusing on patient outcomes by reviewing monitoring data and catching false positive detections without compromising sensitivity.”